Treating Anemic Patients With Myelofibrosis in the New Janus Kinase Inhibitor Era: Current Evidence and Real-world Implications

Bibliographic Details
Published in:	HemaSphere
Main Authors:	Aaron T. Gerds, Prithviraj Bose, Gabriela S. Hobbs, Andrew T. Kuykendall, Lynn M. Neilson, Jinlin Song, Barbara Klencke, Claire N. Harrison
Format:	Article
Language:	English
Published:	Wiley 2022-10-01
Online Access:	http://journals.lww.com/10.1097/HS9.0000000000000778

Similar Items

Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors
by: Randhawa Jasleen, et al.
Published: (2012-08-01)

B03 | PELABRESIB IN COMBINATION WITH RUXOLITINIB FOR JANUS KINASE INHIBITOR-NAIVE PATIENTS WITH MYELOFIBROSIS: 72-WEEK FOLLOW-UP WITH LONG-TERM EFFICACY OUTCOMES OF THE PHASE III MANIFEST-2
by: A. Vannucchi, et al.
Published: (2025-09-01)

S195: MOMENTUM: PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) IN SYMPTOMATIC AND ANEMIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR
by: S. Verstovsek, et al.
Published: (2022-06-01)

JAK inhibitors and myelofibrosis, Einstein and ruxolitinib
by: Claire Harrison
Published: (2015-04-01)

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
by: Prithviraj Bose, et al.
Published: (2020-08-01)

P1044: REDUCTION IN RED BLOOD CELL TRANSFUSION BURDEN: A NOVEL LONGITUDINAL TIME-DEPENDENT ANALYSIS IN PATIENTS WITH TRANSFUSION-DEPENDENT MYELOFIBROSIS TREATED WITH MOMELOTINIB
by: Claire Harrison, et al.
Published: (2023-08-01)

Janus Kinase Inhibitors and Cell Therapy
by: Amer Assal, et al.
Published: (2021-08-01)

JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis
by: Andrew T. Kuykendall, et al.
Published: (2021-08-01)

Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study
by: Ruben A. Mesa, et al.
Published: (2023-11-01)

Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study
by: Rosa Ayala, et al.
Published: (2023-05-01)

Treatment of Myeloproliferative Neoplasms With Janus Kinase Inhibitors: A Meta‐Analysis of Cardiovascular Safety
by: Roberta Dunn, et al.
Published: (2025-02-01)

Janus kinase inhibitors in the treatment of psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2022-02-01)

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
by: Vishal R. Tandon, et al.
Published: (2022-07-01)

Janus Kinase inhibitors in dermatology: a review
by: Bárbara Vieira-Granja, et al.
Published: (2023-01-01)

Janus kinase inhibitors in autoimmune bullous diseases
by: Dawei Huang, et al.
Published: (2023-07-01)

Janus Kinase Inhibitors in the Treatment of Alopecia Areata
by: Athanasios J. Stefanis
Published: (2023-02-01)

The Ongoing Challenges of Managing Cytopenic Myelofibrosis in 2025: The Emergence of Non-JAK Inhibitor Therapies
by: Reynolds SB, et al.
Published: (2025-09-01)

Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial
by: Ruben A. Mesa, et al.
Published: (2021-05-01)

Assessment of interleukin-10 level and Janus kinase 2 V617F mutation incidence in patients with primary myelofibrosis
by: Shahla′a Fadhil Sabir
Published: (2016-01-01)

Intraocular infections following biologicals and Janus Kinase inhibitors
by: Parthopratim Dutta Majumder, et al.
Published: (2025-08-01)

The Upadacitinib - New Janus Kinase Inhibitor - Literature Review
by: Michalina Grzelka, et al.
Published: (2024-08-01)

Janus kinase inhibitors: between prescription authorization and reimbursability
by: F.R. Spinelli, et al.
Published: (2023-12-01)

Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
by: Izabella Ryguła, et al.
Published: (2023-12-01)

Refractory mogamulizumab-associated rash responding to an oral Janus kinase inhibitor
by: Carine M. Lama, MS, et al.
Published: (2023-08-01)

Mayor Erythropoietic Response after Deferasirox Treatment in a Transfusion-Dependent Anemic Patient with Primary Myelofibrosis
by: Del Corso Lisette, et al.
Published: (2013-01-01)

S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS)
by: Pankit Vachhani, et al.
Published: (2023-08-01)

A lymphatic-absorbed multi-targeted kinase inhibitor for myelofibrosis therapy
by: Brian D. Ross, et al.
Published: (2022-08-01)

The Use of Janus Kinase Inhibitors in Axial Spondyloarthritis: Current Insights
by: Eric Toussirot
Published: (2022-02-01)

Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders
by: Robert Roskoski, Jr.
Published: (2022-09-01)

Janus kinase inhibitors are potential therapeutics for amyotrophic lateral sclerosis
by: Peter J. Richardson, et al.
Published: (2023-10-01)

In Silico and In Vitro Study of Janus Kinases Inhibitors from Naphthoquinones
by: Kamonpan Sanachai, et al.
Published: (2023-01-01)

Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition
by: Dionysis Nikolopoulos, et al.
Published: (2023-06-01)

S167: EFFICACY AND SAFETY OF LUSPATERCEPT FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH MYELOFIBROSIS: RESULTS FROM THE ACE-536-MF-001 STUDY
by: Aaron T. Gerds, et al.
Published: (2023-08-01)

P1018: UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS
by: Marina Kremyanskaya, et al.
Published: (2023-08-01)

Janus kinase inhibitors – a role for the treatment of cutaneous T-cell lymphomas?
by: Sarah E. Packer, et al.
Published: (2025-08-01)

Janus kinase inhibitors for alopecia areata: a review of clinical data
by: Yutong Sun, et al.
Published: (2025-05-01)

Janus kinase inhibitors in atopic dermatitis: an umbrella review of meta-analyses
by: Qingying He, et al.
Published: (2024-02-01)

Janus Kinase Inhibitors as Successful Treatment Alternative in Dupilumab-Induced Psoriasis
by: Lina Weiss, et al.
Published: (2024-06-01)

Nonclinical evaluations of deucravacitinib and Janus kinase inhibitors in homeostatic and inflammatory pathways
by: Brandon Johnson, et al.
Published: (2024-09-01)

Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus
by: Huo R, et al.
Published: (2023-04-01)